407 related articles for article (PubMed ID: 18495286)
1. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
[TBL] [Abstract][Full Text] [Related]
3. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
4. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
5. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
Yki-Järvinen H
Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
[TBL] [Abstract][Full Text] [Related]
6. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
7. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
8. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
[TBL] [Abstract][Full Text] [Related]
9. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
Dailey G; Strange P
Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
[TBL] [Abstract][Full Text] [Related]
10. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
11. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
13. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
14. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine: a long-acting insulin for diabetes mellitus.
Garces K
Issues Emerg Health Technol; 2003 Nov; (52):1-4. PubMed ID: 14626260
[TBL] [Abstract][Full Text] [Related]
16. Insulin analogues in the management of diabetes.
Vázquez-Carrera M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2004; 26(6):445-61. PubMed ID: 15349139
[TBL] [Abstract][Full Text] [Related]
17. [Insulin analogues: place of detemir (levemir)].
Dorchy H; Sternon J
Rev Med Brux; 2006; 27(2):89-94. PubMed ID: 16736846
[TBL] [Abstract][Full Text] [Related]
18. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
19. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
[TBL] [Abstract][Full Text] [Related]
20. Insulin glargine for type 2 diabetes.
Hemraj F; Garces K
Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
